Navigation Links
Anemic Patients With MDS Gain Long-Term Benefits From Erythropoietin and Myeloid Growth Factor Hormones
Date:9/17/2009

WASHINGTON, Sept. 17 /PRNewswire-USNewswire/ -- Myelodysplastic syndromes (MDS), a group of blood disorders that can lead to acute myeloid leukemia (AML) in some patients, often cause severe anemia (when the body lacks a sufficient number of functional red blood cells). While certain treatments can help manage the symptoms of anemia, some studies have suggested that they may lead to complications. A new study, however, demonstrates that MDS patients with anemia may benefit from treatment with an erythropoietin (EPO)-based regimen plus supportive care without added complications as compared with those receiving supportive care alone. The study will appear in the September 17 issue of Blood, the official journal of the American Society of Hematology.

The phase III prospective, randomized trial, conducted by research teams of the Eastern Cooperative Oncology Group, was designed to evaluate the efficacy and safety of EPO with or without myeloid growth factor treatment (G-CSF, or granulocyte colony-stimulating factor) and supportive care (SC) with red blood cell transfusions for patients with early-stage MDS (n=53), in comparison to supportive care alone (n=57).

For the study, the researchers followed MDS treatment and dosing guidelines recommended by the National Comprehensive Cancer Network, which include managing anemia with erythropoiesis-stimulating agents (ESAs) such as EPO. EPO is a drug that imitates the action of the hormone erythropoietin, which stimulates the body to produce more red blood cells. Generally, therapy with G-CSF interacts with EPO treatment synergistically to improve erythroid (red blood cell) responses, especially in MDS patients that do not respond to EPO alone.

"EPO is a recommended treatment for MDS, but the combination with G-CSF and supportive care required comparative studies in this patient population," according to lead study author Peter Green
'/>"/>

SOURCE American Society of Hematology
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novel Small Molecule Therapy Shows Benefit for Anemic Patients Via Hydration of Red Blood Cells
2. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
3. Alexza Announces Preliminary Results from its AZ-104 (Staccato(R) Loxapine) Phase 2b Trial in Patients with Migraine Headache
4. Transave Announces Positive Phase II Results For Once-Daily ARIKACE(TM) in the Treatment of Non-CF Bronchiectasis Patients Who Have Pseudomonas Lung Infections
5. Schering-Plough Reports Long-Term Vicriviroc Data From Phase II Open-Label Extension Study in Treatment-Experienced HIV-Infected Patients
6. Two New Studies Report Increased Survival Rates in Tamiflu(R)-Treated Patients with Avian Flu (H5N1) and Severe Seasonal Flu
7. New Data Show Patients With Chronic Low Back Pain Maintained Pain Reduction on Cymbalta(R)
8. Yoga Benefits Back-Pain Patients
9. Two-Year SYNTAX Data Show Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) EXPRESS(R) Stents and Bypass Surgery
10. CRESTOR(R) Reduced Risk of Cardiovascular Events in Elderly Patients in New Analysis of Jupiter
11. New Large-Scale, Global Study Provides Additional Information About an Intensified Dose-Regimen of PLAVIX(R) in Acute Coronary Syndrome Patients Undergoing Angioplasty
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... JOSE, Calif. , Oct. 1, 2014  SI-BONE, Inc., ... iFuse Implant System, ® a minimally invasive surgical (MIS) ... (SI) joint, today announced the expansion of its European operations ... Mr. Eric Schaber as General Manager, Germany.  Mr. ... currently vice president of Europe , ...
(Date:10/1/2014)... Switzerland , October 1, 2014 ... and Next Generation Sequencing (NGS) data analysis, today launches ... full cystic fibrosis analysis in a single NGS experiment. ... of all types of variants in a single NGS ... now, it has not been possible to simultaneously analyse ...
(Date:9/30/2014)... , Sept. 30, 2014  Hologic, Inc. (NASDAQ: ... MacMillan , Hologic,s President and Chief Executive Officer, will ... on October 1, the first day of Breast Cancer ... the Company,s campaign focused on the important benefits of ... by the FDA as clinically superior to traditional mammography. ...
Breaking Medicine Technology:SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 2SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 3SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 4Sophia Genetics Launches Full CFTR Analysis in Single Clinical Grade NGS Experiment 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 3
... Water Street Healthcare Partners , a strategic private ... announced today that it has completed a sale and ... CareCentrix is the nation,s leading provider of ... industry.  Water Street sold its majority interest in CareCentrix ...
... COPENHAGEN, Denmark and LAGUNA NIGUEL, Calif., Sept. 20, ... today announced that the two companies have entered ... manufacture of bulk IB1001, Inspiration,s intravenous recombinant factor ... of bleeding in individuals with hemophilia B. Under ...
Cached Medicine Technology:Water Street Healthcare Partners Completes Sale and Recapitalization of CareCentrix 2Water Street Healthcare Partners Completes Sale and Recapitalization of CareCentrix 3CMC Biologics Enters Commercial Supply Agreement with Inspiration Biopharmaceuticals for IB1001 2CMC Biologics Enters Commercial Supply Agreement with Inspiration Biopharmaceuticals for IB1001 3
(Date:10/1/2014)... Engineering and Physical Sciences Research Council (EPSRC) will ... industrial control systems which run, for example, manufacturing ... rail network. , The research will help ... infiltrating the systems behind our critical national infrastructure. ... Control Systems (RITICS), based at Imperial College London, ...
(Date:10/1/2014)... Familylifeinsurancequotes.org has released a new blog ... citizens. , Senior citizens can qualify for affordable ... to seniors who are over 50 years old. Some ... a medical examination. , Term life insurance with a ... can qualify. Having life insurance during retirement is important ...
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new blog ... prices for smokers. , Smoking will always have a ... is the best method to find affordable coverage. Insurance ... need coverage. , Whole life insurance premiums will ... Since the coverage is permanent, the initial rates ...
(Date:10/1/2014)... Farmington Company today announced it ... and visual identity helping brokers, consultants and companies ... to create greater benefit communication synergies. They unveiled ... empowering customers to better leverage Farmington Company’s industry-tested ... of the rebrand is the refreshed tagline: For ...
(Date:10/1/2014)... Maine (PRWEB) October 01, 2014 Between ... disorders in the U.S., according to figures from the ... Related Diseases Association (AARDA), and many of them have ... chance of having undiagnosed celiac disease. Gluten Free ... raise awareness of undiagnosed celiac disease by publishing a ...
Breaking Medicine News(10 mins):Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3
... The U.S. Food and Drug Administration (FDA) has decided ... (R) (infliximab) to be used in the treatment of ... today. Crohn's disease affects the gastrointestinal tract and causes ... now there is no drug to treat children who ...
... Illinois at Chicago in collaboration with their colleagues from ... enzyme in the virus that causes SARS//, severe acute ... in the March 27 issue of the Proceedings of ... form a new drug target for drug makers. ...
... the cause of four men whose lives took a turn ... German company// TeGenero and medical research company Parexel, has received ... handling the case, has felt ignored after receiving no response ... conducted at Northwick Park Hospital in Harrow, north-west London, last ...
... It is already known to us that some popular spices ... Liu, an assistant professor of obstetrics// and gynecology at the ... powder dissolved in solution by putting it on ovarian cancer ... that ginger can kill ovarian cancer cells. But the study ...
... Harris Interactive? for the Vagisil Women's Health CenterSM conducted a ... of today's American women are taking active roles in their ... thirds of women aged 18 and older (63 percent) report ... go to a gynecologist, 61 percent say they "always" go ...
... the risk of coronary heart attack and could in general be ... study of 4,400 men and women aged 65 and over by ... a link between the amount of alcohol drunk and the likelihood ... ,People who drink 14 or more glasses of wine or ...
Cached Medicine News:Health News:FDA Accords Priority Review For Pediatric Crohn's Disease Drug 2Health News:Spices Could Be Employed To Treat Certain Cancers 2Health News:Women aware of “feminine health” : their attitud 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: